1,732,000 Shares in Kenvue Inc. $KVUE Bought by Empyrean Capital Partners LP

Empyrean Capital Partners LP purchased a new position in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,732,000 shares of the company’s stock, valued at approximately $29,877,000.

A number of other institutional investors also recently bought and sold shares of the stock. Capitolis Liquid Global Markets LLC lifted its position in Kenvue by 1,116.8% in the fourth quarter. Capitolis Liquid Global Markets LLC now owns 10,950,999 shares of the company’s stock worth $188,905,000 after buying an additional 10,050,999 shares during the last quarter. Cinctive Capital Management LP bought a new stake in Kenvue in the fourth quarter worth $629,000. Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Kenvue by 325.9% in the fourth quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 907,987 shares of the company’s stock worth $15,702,000 after buying an additional 694,784 shares during the last quarter. Armistice Capital LLC bought a new stake in Kenvue in the fourth quarter worth $68,865,000. Finally, Caisse de depot et placement du Quebec lifted its position in Kenvue by 1,983.3% in the fourth quarter. Caisse de depot et placement du Quebec now owns 875,000 shares of the company’s stock worth $15,094,000 after buying an additional 833,000 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on KVUE. Barclays lowered their price target on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Argus upgraded Kenvue to a “hold” rating in a research note on Friday, March 6th. Citigroup reduced their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 15th. Canaccord Genuity Group increased their target price on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, UBS Group reduced their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Stock Performance

KVUE stock opened at $18.03 on Thursday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The business’s fifty day simple moving average is $17.49 and its two-hundred day simple moving average is $17.56. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $22.87. The firm has a market cap of $34.61 billion, a price-to-earnings ratio of 21.21, a PEG ratio of 1.40 and a beta of 0.54.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter last year, the firm posted $0.24 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Activity at Kenvue

In other news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.